
24/07/2025
A research team including University of Arizona Comprehensive Cancer Center members Steffan T. Nawrocki, PhD, and Jennifer S. Carew, PhD, have identified a novel biomarker that may predict which patients with clear cell renal cell carcinoma (ccRCC) are most likely to benefit from a targeted combination therapy involving autophagy inhibition.
“This could be an important step toward personalizing treatment for patients with advanced renal cell carcinoma,” said Nawrocki.
https://cancercenter.arizona.edu/news/2025/07/u-cancer-center-researchers-identify-biomarker